Treatment of Recurrent Genital Herpes Flare-Up
For a recurrent genital herpes flare-up in an immunocompetent adult, initiate episodic antiviral therapy immediately at the first sign of prodrome or lesions with one of the following regimens: acyclovir 400 mg three times daily for 5 days, acyclovir 800 mg twice daily for 5 days, famciclovir 125 mg twice daily for 5 days, or valacyclovir 500 mg twice daily for 5 days. 1
Episodic Treatment Strategy
The key to effective episodic therapy is early initiation—ideally during the prodrome or within 1 day of lesion onset. Patients should be provided with antiviral medication or a prescription in advance so they can start treatment immediately when symptoms begin 1. This patient-initiated approach is critical because delayed treatment significantly reduces clinical benefit 2.
Recommended Episodic Regimens (Choose One):
- Acyclovir 400 mg orally three times daily for 5 days, OR
- Acyclovir 200 mg orally five times daily for 5 days, OR
- Acyclovir 800 mg orally twice daily for 5 days, OR
- Famciclovir 125 mg orally twice daily for 5 days, OR
- Valacyclovir 500 mg orally twice daily for 5 days 1
All these regimens have comparable efficacy. The choice depends on dosing convenience—valacyclovir and famciclovir offer simpler twice-daily dosing, which may improve adherence during prolonged treatment 1.
When to Consider Suppressive Therapy Instead
If the patient experiences 6 or more recurrences per year, switch from episodic to daily suppressive therapy, which reduces recurrence frequency by ≥75% 1. This dramatically improves quality of life for patients with frequent outbreaks.
Recommended Suppressive Regimens (Choose One):
- Acyclovir 400 mg orally twice daily, OR
- Famciclovir 250 mg orally twice daily, OR
- Valacyclovir 500 mg orally once daily, OR
- Valacyclovir 1000 mg orally once daily 1
Important caveat: Valacyclovir 500 mg once daily is less effective in patients with ≥10 episodes per year—use higher doses or twice-daily regimens for these patients 1.
Safety data support acyclovir use for up to 6 years continuously, with valacyclovir and famciclovir documented for 1 year 1. After 1 year of suppressive therapy, reassess whether to continue based on recurrence patterns and patient preference, as recurrence frequency naturally decreases over time in many patients 1.
Critical Counseling Points
Transmission risk persists even without visible lesions. Asymptomatic viral shedding occurs more frequently with HSV-2 than HSV-1 and during the first 12 months after infection 1. Patients must:
- Abstain from sexual activity when lesions or prodromal symptoms are present
- Use condoms during all sexual exposures with new or uninfected partners
- Inform sexual partners of their HSV status 1
Suppressive therapy reduces but does not eliminate asymptomatic shedding, so its effect on preventing transmission is incomplete 1.
Common Pitfalls to Avoid
Do not use topical acyclovir—it is substantially less effective than oral therapy and should be avoided 3.
Do not delay treatment. The 1993 guidelines noted that most immunocompetent patients with recurrent disease do not benefit from acyclovir if treatment cannot be started early 3. However, the 1998 guidelines clarified that when treatment is started during prodrome or within 1 day of lesion onset, patients do benefit from episodic therapy 1. This underscores the absolute necessity of patient-initiated therapy.
Resistance is not a concern in immunocompetent patients. Acyclovir-resistant strains have been isolated during suppressive therapy but have not been associated with treatment failure in immunocompetent individuals 1, 3.
Special Populations
For severe disease requiring hospitalization (disseminated infection, pneumonitis, hepatitis, meningitis, or encephalitis), use acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days until clinical resolution 1, 3.
For pregnant women and immunocompromised patients, management requires specific modifications beyond the scope of standard recurrent episode treatment 4.